In the univariable survival analysis, patients with CD5+ DLBCL showed significantly shorter OS (p = 0.025) and PFS (p = 0.033) than those with CD5- tumors (Fig 3), whereas DE lymphomas revealed inferior PFS (p = 0.036) but not OS (p = 0.234) (Fig 4). This evidence concerns the gene CD5 and lymphoma.